DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data.
DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data.
复制标题
DOI：
10.1186/1471-2105-14-316
复制
发表时间：
2013-11-04
影响因子：
3
通讯作者：
Santos A
中科院分区：
文献类型：
--
作者：
Ortuño JE;Ledesma-Carbayo MJ;Simões RV;Candiota AP;Arús C;Santos A
DCE@urLAB是一款用于分析动态对比增强磁共振成像数据（DCE-MRI）的软件应用程序。该工具结合了一个友好的图形用户界面（GUI），以交互方式选择和分析图像集内的感兴趣区域（ROI），同时考虑到造影剂（CA）的组织浓度及其对像素强度的影响。通过使用Levenberg-Marquardt算法（LMA）将DCE-MRI数据拟合到几个药代动力学模型来估计基于像素模型的定量参数。DCE@urLAB还包括实践中常用的半定量参数和启发式分析方法。该软件应用程序已在交互式数据语言（IDL）编程，并与公开可用的模拟数据和临床前研究荷瘤小鼠大脑进行了测试。在临床前研究中应用药代动力学和非定量分析DCE-MRI的用户友好的解决方案已经实施和测试。建议的工具已被专门设计用于轻松选择多像素的ROI。DCE@urLAB的公开版本以及开放源代码和示例数据集可在http://www.die.upm.es/im/archives/DCEurLAB/上获得。
DCE@urLAB is a software application for analysis of dynamic contrast-enhanced magnetic resonance imaging data (DCE-MRI). The tool incorporates a friendly graphical user interface (GUI) to interactively select and analyze a region of interest (ROI) within the image set, taking into account the tissue concentration of the contrast agent (CA) and its effect on pixel intensity. Pixel-wise model-based quantitative parameters are estimated by fitting DCE-MRI data to several pharmacokinetic models using the Levenberg-Marquardt algorithm (LMA). DCE@urLAB also includes the semi-quantitative parametric and heuristic analysis approaches commonly used in practice. This software application has been programmed in the Interactive Data Language (IDL) and tested both with publicly available simulated data and preclinical studies from tumor-bearing mouse brains. A user-friendly solution for applying pharmacokinetic and non-quantitative analysis DCE-MRI in preclinical studies has been implemented and tested. The proposed tool has been specially designed for easy selection of multi-pixel ROIs. A public release of DCE@urLAB, together with the open source code and sample datasets, is available at http://www.die.upm.es/im/archives/DCEurLAB/.
登录
查看更多内容
影响因子：
8.8
作者：
Leach MO;Brindle KM;Evelhoch JL;Griffiths JR;Horsman MR;Jackson A;Jayson GC;Judson IR;Knopp MV;Maxwell RJ;McIntyre D;Padhani AR;Price P;Rathbone R;Rustin GJ;Tofts PS;Tozer GM;Vennart W;Waterton JC;Williams SR;Workman P;Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK
通讯作者：
Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK
影响因子：
2.9
作者：
Delgado-Goni, T.;Martin-Sitjar, J.;Arus, C.
通讯作者：
Arus, C.
影响因子：
2.9
作者：
Kim, Jae-Hun;Im, Geun Ho;Lee, Jung Hee
通讯作者：
Lee, Jung Hee
影响因子：
4.4
作者：
Barboriak, Daniel P.;MacFall, James R.;Dewhirst, Mark W.
通讯作者：
Dewhirst, Mark W.
影响因子：
3.3
作者：
Cha, S;Johnson, G;Turnbull, DH
通讯作者：
Turnbull, DH